Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 153-161

  Engman, Lars ^a   Al Maharik, Nawaf ^a   McNaughton, Michael ^a   Birmingham, Anne ^b   Powis, Garth ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antioxidant; Antitumor activity; Organotellurium compound; Thioredoxin reductase

Indexed keywords

4 [N (2 CARBOMETHOXYETHYL)AMINO]PHENYL 3 PHENOXYPROPYL TELLURIDE; 4 [N (2 CARBOMETHOXYETHYL)AMINO]PHENYL 4 PHENOXYBUTYL TELLURIDE; 4 [N,N BIS(2 CARBOMETHOXYETHYL)AMINO]PHENYL 3 PHENOXYBUTYL TELLURIDE; 4 [N,N BIS(2 CARBOMETHOXYETHYL)AMINO]PHENYL 3 PHENOXYPROPYL TELLURIDE; 4 [N,N BIS(2 CARBOXYETHYL)AMINO]PHENYL 3 PHENOXYBUTYL TELLURIDE; 4 [N,N BIS(2 CARBOXYETHYL)AMINO]PHENYL 3 PHENOXYPROPYL TELLURIDE; ALPHA TOCOPHEROL DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIS[4 [N (2 CARBOMETHOXYETHYL)AMINO]PHENYL]TELLURIDE; BIS[4 [N,N BIS(2 CARBOMETHOXYETHYL)AMINO]PHENYL]TELLURIDE; BIS[4 [N,N BIS(CARBOXYETHYL)AMINO]PHENYL]TELLURIDE TETRASODIUM; ORGANOTELLURIUM DERIVATIVE; OXIDOREDUCTASE INHIBITOR; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTIOXIDANTS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; ORGANOMETALLIC COMPOUNDS; OXIDATION-REDUCTION; TELLURIUM; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TUMOR CELLS, CULTURED;

EID: 0037331676     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00009     Document Type: Article

References (37)

1. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000; 346:1.
2. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Rad Biol Med 2000; 29:312.
3. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Human Pathol 2000; 31:475.
4. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994; 1218:292.
5. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson JȦ. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 1997; 272:2936.
6. Bodenstein J, Follmann H. Characterization of two thioredoxins in pig heart including a new mitochondrial protein. Z Naturforsch 1991; 46c:270.
7. Tanaka T, Hosoi F, Yamaguchi-Iwai Y, Nakamura H, Masutani H, Ueda S, et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J 2002; 21:1695.
8. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001; 41:261.
9. Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, et al. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res 1996; 56:5765.
10. Oblong JE, Berggren M, Gasdaska PY, Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem 1994; 269:11714.
11. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996; 16:3459.
12. Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, et al. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 1991; 68:1583.
13. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992; 69:2091.
14. Gallegos A, Raffel J, Bhattacharyya AK, Powis G. Increased expression of thioredoxin in human primary and metastatic colon cancer. Am Ass Cancer Res 2000; 41:189.
15. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prevent 2000; 24:53.
16. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression associates with lymph node status and prognosis in early operable non small cell lung cancer (NSCLC). Clin Cancer Res 2001; 7:3087.
17. Becker K, Gromer S, Schirmer RH, Müller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000; 267:6118.
18. May S.W. Selenium-based drug design: rationale and therapeutic potential. Exp Opin Invest Drugs 1999; 8:1017.
19. Zhong L, Arnér ES. J, Ljung J, Ȧslund F, Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carbozyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem 1998; 273:8581.
20. Gromer S, Schirmer RH, Becker K. The 58 Kda mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett 1997; 412:318.
21. Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anti-Cancer Drug Des 1997; 12:659.
22. Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, et al. Mechanism of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998; 55:987.
23. Kirkpatrick DL, Watson S, Kunkel M, Fletcher S, Ulhaq S, Powis G. Parallel synthesis of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents. Anti-Cancer Drug Des 1999; 14:421.
24. Engman L, Cotgreave I, Angulo M, Powis G. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anticancer Res 1997; 17:4599.
25. Engman L, Kanda T, Gallegos A, Williams R, Powis G. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anti-Cancer Drug Des 2001; 15:303.
26. Vessman K, Ekström M, Berglund M, Andersson C-M, Engman L. Catalytic antioxidant activity of diaryl tellurides in a two-phase lipid peroxidation model. J Org Chem 1995; 60:4461.
27. Hi reactions. J Org Chem 1999; 64:6764.
28. Malmström J, Jonsson M, Cotgreave IA, Hammarstöm L, Sjödin M, Engman L. The antioxidant profile of 2,3-dihydrobenzo[b]furan-5-ol and its thio, 1-seleno, 1-telluro analogues. J Am Chem Soc 2001; 123:3434.
29. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55.
30. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936.
31. Kanda T, Engman L, Cotgreave IA, Powis G. Novel water-soluble diorganyl tellurides with thiol peroxidase and antioxidant activity. J Org Chem 1999; 64:8161.
32. Shanks D, Al-Maharik N, Malmström J, Engman L, Eriksson P, Stenberg B, et al. Improved antioxidant formulations for polymeric materials-synergistic protective effects in combinations of organotellurium compounds with conventional phenolic antioxidants and thiols. Macromolecules 2003; submitted.
33. co. J Am Chem Soc 1954; 76:5708.
34. 2 using an organotelluride catalyst. Org Lett 2001; 3:349.
35. Francavilla C, Drake MD, Bright FV, Detty MR. Dendrimeric organochalcogen catalysts for the activation of hydrogen peroxide: improved catalytic activity through statistical effects and cooperativity in successive generations. J Am Chem Soc 2001; 123:57.
36. Johnson & Johnson Clinical Diagnostics, Inc. EP Application 0,747,704,A2; 1996.
37. Wieslander E, Engman L, Svensjö E, Erlansson M, Johansson U, Linden M, et al. Antioxidative properties of organotellurium compounds in cell systems. Biochem Pharmacol 1998; 55:573.